Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Boehringer Ingelheim Identifier:
First received: October 12, 2009
Last updated: August 18, 2014
Last verified: August 2014

The study aim is to determine maximally tolerated dose (MTD) of BIBF 1220 in HCC (hepatocellular cancer) and compare efficacy of BIBF 1120 to Sorafenib in HCC patients

Condition Intervention Phase
Carcinoma, Hepatocellular
Drug: Sorafenib
Drug: BIBF 1120
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multicenter, Open Label, Phase I /Randomised Phase II Study to Evaluate Safety, Pharmacokinetics and Efficacy of BIBF 1120 in Comparison With Oral Sorafenib for Advanced Hepatocellular Carcinoma Patients.

Resource links provided by NLM:

Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • Maximum Tolerated Dose (phase I) [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
  • Time to tumor progression according to RECIST 1.0 by central independent review (phase II) [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Objective tumor response according to RECIST 1.0 (phase II) [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
  • Progression free survival according to RECIST 1.0 (phase II) [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
  • Overall survival (phase II) [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Incidence of DLTs (phase I) [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 125
Study Start Date: October 2009
Estimated Study Completion Date: January 2015
Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BIBF 1120
Phase I dose escalation and phase II using dose determined in phase I ( 200 mg BID)
Drug: Sorafenib
Twice daily dosing
Drug: BIBF 1120
MTD defined in phase I, phase II vs. Sorafenib comparison
Active Comparator: Sorafenib
Twice daily dosing in phase II
Drug: BIBF 1120
MTD defined in phase I, phase II vs. Sorafenib comparison
Drug: Sorafenib
Twice daily dosing


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Histologically confirmed diagnosis of hepatocellular cancer (HCC) not amenable to local therapy
  • Age 18 years or older
  • Eastern Cooperative Oncology Group performance score of 2 or less
  • at least one untreated measurable lesion according to Response Evaluation Criteria In Solid Tumors (RECIST); lesion previously treated by local therapy - radiofrequency ablation, percutaneous ethanol injection, radiotherapy, transarterial chemoembolization - must have documented progression according to Response Evaluation Criteria In Solid Tumors (RECIST) by computed tomography (CT) or magnetic resonance imaging (MRI) (this criterion is limited to phase II only and, patients with non-measurable tumors are allowed in phase I)
  • Time interval from last local therapy (radiofrequency ablation, percutaneous ethanol injection, radiotherapy, transarterial chemoembolization) more than 4 weeks prior to registration
  • Written informed consent consistent with International Conference on Harmonisation/ Good Clinical Practice (ICH-GCP) and local legislation

Exclusion criteria:

  • Fibrolamellar hepatocellular cancer (HCC)
  • Uncontrolled or refractory ascites
  • Barcelona Clinic Liver Cancer (BCLC) stage D
  • Hepatic encephalopathy grade II or higher
  • Prothrombin time international normalized ratio greater than 2.3, or prothrombin time more than 6 seconds prolonged than control
  • Absolute neutrophil count less than 1000 /mL
  • Platelet count less than 60000 /mL
  • Hemoglobin less than 9 g/dL
  • Serum creatinine greater than 1.5 times Upper Limit of Normal (ULN)
  • Proteinuria of Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or greater
  • Variceal bleeding within last 3 months prior to registration
  • History of major thrombotic (except portal vein thrombosis) or clinically relevant major bleeding event in the past 6 months
  • Known inherited predisposition to bleeding or thrombosis
  • Significant cardiovascular diseases (i.e. hypertension not controlled by medical therapy, blood pressure > 150/90 mmHg), unstable angina, history of myocardial infarction within the past 6 months, congestive heart failure > class II according to New York Heart Association (NYHA), serious cardiac arrhythmia, pericardial effusion)
  • Therapeutic anticoagulation (except low dose heparin and/or heparin flush as needed for maintenance of an indwelling intravenous device) or antiplatelet therapy (except for chronic low-dose therapy with acetylsalicylic acid =< 325mg per day)
  • Major surgery within 4 weeks prior to registration
  • Treatment with other investigational drugs or participation in another clinical trial within the past four weeks before start of therapy or concomitantly with this trial (except for present trial drug)
  • Serious illness or concomitant non-oncological disease such as neurologic, psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may increase the risk associated with study participation or study drug administration and in the judgment of the investigator would make the patient inappropriate for entry into the study
  • Patients who are sexually active and unwilling to use a medically acceptable method of contraception (e.g. such as implants, injectables, combined oral contraceptives, some intrauterine devices or vasectomized partner for participating females, condoms for participating males) during the trial and for at least twelve months after end of active therapy
  • Current alcohol abuse or drug abuse that would limit pt ability to comply with protocol
  • Symptomatic central nervous system (CNS) metastasis
  • Life expectancy less than 12 weeks
  • Patient unable to take oral medication
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01004003

1199.37.43001 Boehringer Ingelheim Investigational Site
Wien, Austria
1199.37.43002 Boehringer Ingelheim Investigational Site
Wien, Austria
1199.37.33001 Boehringer Ingelheim Investigational Site
Paris, France
1199.37.33002 Boehringer Ingelheim Investigational Site
Paris, France
1199.37.49008 Boehringer Ingelheim Investigational Site
Berlin, Germany
1199.37.49009 Boehringer Ingelheim Investigational Site
Erlangen, Germany
1199.37.49002 Boehringer Ingelheim Investigational Site
Freiburg, Germany
1199.37.49001 Boehringer Ingelheim Investigational Site
Hannover, Germany
1199.37.49010 Boehringer Ingelheim Investigational Site
Heidelberg, Germany
1199.37.49005 Boehringer Ingelheim Investigational Site
Jena, Germany
1199.37.49004 Boehringer Ingelheim Investigational Site
Magdeburg, Germany
1199.37.49003 Boehringer Ingelheim Investigational Site
München, Germany
1199.37.49006 Boehringer Ingelheim Investigational Site
Tübingen, Germany
1199.37.36001 Boehringer Ingelheim Investigational Site
Debrecen, Hungary
1199.37.31002 Boehringer Ingelheim Investigational Site
Leiden, Netherlands
1199.37.31001 Boehringer Ingelheim Investigational Site
Utrecht, Netherlands
1199.37.48002 Boehringer Ingelheim Investigational Site
Olsztyn, Poland
1199.37.48003 Boehringer Ingelheim Investigational Site
Warsaw, Poland
1199.37.48001 Boehringer Ingelheim Investigational Site
Warszawa, Poland
1199.37.40002 Boehringer Ingelheim Investigational Site
Bucharest, Romania
1199.37.40003 Boehringer Ingelheim Investigational Site
Cluj-Napoca, Romania
United Kingdom
1199.37.44001 Boehringer Ingelheim Investigational Site
Edgbaston, Birmingham, United Kingdom
1199.37.44005 Boehringer Ingelheim Investigational Site
Glasgow, United Kingdom
1199.37.44008 Boehringer Ingelheim Investigational Site
Liverpool, United Kingdom
1199.37.44002 Boehringer Ingelheim Investigational Site
London, United Kingdom
1199.37.44003 Boehringer Ingelheim Investigational Site
London, United Kingdom
1199.37.44006 Boehringer Ingelheim Investigational Site
Manchester, United Kingdom
1199.37.44004 Boehringer Ingelheim Investigational Site
Nottingham, United Kingdom
Sponsors and Collaborators
Boehringer Ingelheim
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

No publications provided

Responsible Party: Boehringer Ingelheim Identifier: NCT01004003     History of Changes
Other Study ID Numbers: 1199.37, 2009-011925-14
Study First Received: October 12, 2009
Last Updated: August 18, 2014
Health Authority: Austria: Medicines and Medical Devices Agency
France: Agence Nationale de Sécurité du Médicament et des produits de santé
Germany: Federal Institute for Drugs and Medical Devices
Hungary: National Institute of Pharmacy
Netherlands: Central Committee Research Involving Human Subjects
Poland: Registration Medicinal Product Medical Device Biocidal Product
Romania: National Medicines Agency
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Additional relevant MeSH terms:
Carcinoma, Hepatocellular
Digestive System Diseases
Digestive System Neoplasms
Liver Diseases
Liver Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses processed this record on July 29, 2015